169 related articles for article (PubMed ID: 36596983)
1. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT.
Jiménez-Ubieto A; Poza M; Martin-Muñoz A; Ruiz-Heredia Y; Dorado S; Figaredo G; Rosa-Rosa JM; Rodriguez A; Barcena C; Navamuel LP; Carrillo J; Sanchez R; Rufian L; Juárez A; Rodriguez M; Wang C; de Toledo P; Grande C; Mollejo M; Casado LF; Calbacho M; Baumann T; Rapado I; Gallardo M; Sarandeses P; Ayala R; Martínez-López J; Barrio S
Leukemia; 2023 Mar; 37(3):659-669. PubMed ID: 36596983
[TBL] [Abstract][Full Text] [Related]
2. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
[TBL] [Abstract][Full Text] [Related]
3. Genetic Profiling of Cell-Free DNA in Liquid Biopsies: A Complementary Tool for the Diagnosis of B-Cell Lymphomas and the Surveillance of Measurable Residual Disease.
Figaredo G; Martín-Muñoz A; Barrio S; Parrilla L; Campos-Martín Y; Poza M; Rufián L; Algara P; De La Torre M; Jiménez Ubieto A; Martínez-López J; Casado LF; Mollejo M
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627050
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.
Bastos-Oreiro M; Suárez-González J; Andrés-Zayas C; Carrión NC; Moreno S; Carbonell D; Chicano M; Muñiz P; Sanz L; Diaz-Crespo FJ; Menarguez J; Diez-Martín JL; Buño I; Martínez-Laperche C
Sci Rep; 2021 Nov; 11(1):22815. PubMed ID: 34819573
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Baseline and Interim Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT in Patients with Follicular Lymphoma.
Liang JH; Zhang YP; Xia J; Ding CY; Wu W; Wang L; Cao L; Zhu HY; Fan L; Li TN; Li JY; Xu W
Cancer Res Treat; 2019 Oct; 51(4):1479-1487. PubMed ID: 30913868
[TBL] [Abstract][Full Text] [Related]
6. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
[TBL] [Abstract][Full Text] [Related]
7. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of baseline
Faudemer J; Aide N; Gac AC; Damaj G; Vilque JP; Lasnon C
Sci Rep; 2021 Dec; 11(1):23812. PubMed ID: 34893676
[TBL] [Abstract][Full Text] [Related]
9. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis.
Novelli S; Briones J; Flotats A; Sierra J
Adv Clin Exp Med; 2015; 24(2):325-30. PubMed ID: 25931367
[TBL] [Abstract][Full Text] [Related]
10. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
Ujjani CS; Hill EM; Wang H; Nassif S; Esposito G; Ozdemirli M; Cordova C; Cheson BD
Br J Haematol; 2016 Aug; 174(3):410-6. PubMed ID: 27098364
[TBL] [Abstract][Full Text] [Related]
11. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
[TBL] [Abstract][Full Text] [Related]
12. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z
Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283
[TBL] [Abstract][Full Text] [Related]
13. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764
[TBL] [Abstract][Full Text] [Related]
16. Limited benefit of additional contrast-enhanced CT to end-of-treatment PET/CT evaluation in patients with follicular lymphoma.
Paone G; Raditchkova-Sarnelli M; Ruberto-Macchi T; Cuzzocrea M; Zucca E; Ceriani L; Giovanella L
Sci Rep; 2021 Sep; 11(1):18496. PubMed ID: 34531504
[TBL] [Abstract][Full Text] [Related]
17. Is it time for PET-guided therapy in follicular lymphoma?
Trotman J; Pettitt AR
Blood; 2022 Mar; 139(11):1631-1641. PubMed ID: 34260714
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological prognostic factors in follicular lymphoma patients.
Jóna Á; Kenyeres A; Barna S; Illés Á; Simon Z
PLoS One; 2022; 17(8):e0272787. PubMed ID: 35925993
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
20. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
